ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Groundbreaking Human Weight Loss Study of a Natural Supplement Exceeds Statistical Significance

Six-month results reached 10.4% weight loss with little loss of lean mass

WEST PALM BEACH, FL / ACCESS Newswire / August 28, 2025 / Tonum Health, a developer of science-backed natural supplements for cognitive performance, weight loss, and metabolic health, today announced results from its open-label six-month human clinical study of Motus, the company's flagship weight loss supplement. The study demonstrated clinically significant weight loss in overweight and obese adults without requiring caloric restriction or exercise. Conducted in the United States across 100 participants (ages 25-68, BMI ≥25), Motus achieved an average total body weight loss of 5.7% at 12 weeks. Among the 40 participants who continued into the 24-week extension phase, average total weight loss rose to 10.4%, with 87% of that loss coming from fat rather than lean mass.

Tonum Health's Motus natural weight loss supplement study participant before and after six months of use.

"This human study validates what we've seen in extensive pre-clinical models-that Motus promotes sustainable fat loss while preserving muscle mass - without caloric restrictions or exercise requirements," said Lance Converse, CEO of Tonum Health. "For consumers and clinicians alike, this represents a meaningful breakthrough: a natural, research-backed weight loss product that comes without the cost, muscle loss, or safety concerns."

Participants were grouped post hoc into behavioral categories based on diet and exercise habits. Results showed a clear dose-response relationship, with greater lifestyle adherence amplifying the supplement's effects:

  • Category 1: 14.83% weight loss (healthy diet + regular exercise 4+ times per week)

  • Category 2: 10.02% weight loss (average diet + exercise 2-3 times per week)

  • Category 3: 8.92% weight loss (average diet + no exercise)

  • Category 4: 7.69% weight loss (poor diet + no exercise)

Importantly, no serious adverse events were reported.

"These findings are significant because they demonstrate that Motus works in real-world conditions, not just in tightly controlled lab settings," said Nicholas Moore, PhD, Chief Scientific Advisor at Tonum Health. "By aligning with people's natural lifestyles, Motus has the potential to fill a major gap in weight management-providing an effective, safe, and accessible option for the millions seeking alternatives to injectable drugs."

This study builds on Tonum Health's prior pre-clinical research, including findings being presented at Obesity Week 2025, which shows Motus enhances fat oxidation and energy expenditure independent of food intake reduction.

# # #

About Tonum Health

Founded in 2018, Tonum Health, a division of Prostasis, develops natural supplements rooted in rigorous scientific research to help promote weight loss, metabolic balance, and healthy cognitive performance and resilience. With a team of pharmaceutical researchers and wellness experts, Tonum is reshaping the way individuals take control of their long-term health - naturally. Learn more at www.tonum.com.

Media Contact:
Leigh Fazzina
Tonum Health
610-316-4126
leigh@tonum.com

SOURCE: Tonum Health



View the original press release on ACCESS Newswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.